Mark Heaney

8.3k total citations · 1 hit paper
91 papers, 4.5k citations indexed

About

Mark Heaney is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Mark Heaney has authored 91 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Genetics, 35 papers in Molecular Biology and 27 papers in Hematology. Recurrent topics in Mark Heaney's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Mark Heaney is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Mark Heaney collaborates with scholars based in United States, Canada and Italy. Mark Heaney's co-authors include David W. Golde, Owen A. O’Connor, David A. Scheinberg, Jeffrey R. Gardner, Paul A. Marks, William Kevin Kelly, Lawrence B. Schwartz, Victoria M. Richon, Joseph G. Jurcic and Howard I. Scher and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Mark Heaney

90 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

2005 739 citations William Kevin Kelly, Owen A. O’Connor et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Heaney United States	31	2.1k	1.0k	962	906	695	91	4.5k
Roshini S. Abraham United States	32	1.7k 0.8×	1.2k 1.2×	619 0.6×	704 0.8×	1.7k 2.4×	126	4.4k
Didier Bouscary France	40	3.5k 1.6×	2.3k 2.2×	1.4k 1.5×	1.1k 1.2×	993 1.4×	163	6.3k
Ulrich Jäger Austria	45	1.8k 0.9×	2.4k 2.3×	1.7k 1.7×	1.2k 1.3×	1.2k 1.7×	172	5.7k
Albert Deisseroth United States	40	2.6k 1.2×	1.1k 1.1×	2.4k 2.5×	658 0.7×	1.0k 1.4×	139	5.7k
Akio Urabe Japan	34	1.1k 0.5×	1.5k 1.5×	1.1k 1.2×	558 0.6×	1.3k 1.8×	163	4.7k
Guy Pratt United Kingdom	41	2.4k 1.1×	1.9k 1.9×	1.8k 1.8×	1.5k 1.7×	1.2k 1.8×	184	5.3k
Sung‐Soo Yoon South Korea	35	1.6k 0.7×	1.8k 1.7×	1.5k 1.5×	637 0.7×	630 0.9×	342	4.2k
Daniel Kirchhofer United States	47	2.4k 1.1×	2.1k 2.0×	660 0.7×	828 0.9×	1.1k 1.6×	116	6.4k
Adam J. Bass United States	38	2.8k 1.3×	379 0.4×	2.1k 2.2×	558 0.6×	474 0.7×	94	5.5k
Laura G. Corral United States	36	2.9k 1.3×	2.8k 2.7×	1.8k 1.8×	856 0.9×	1.4k 2.1×	61	6.0k

Countries citing papers authored by Mark Heaney

Since Specialization

Citations

This map shows the geographic impact of Mark Heaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Heaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Heaney more than expected).

Fields of papers citing papers by Mark Heaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Heaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Heaney. The network helps show where Mark Heaney may publish in the future.

Co-authorship network of co-authors of Mark Heaney

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Heaney. A scholar is included among the top collaborators of Mark Heaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Heaney. Mark Heaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeAngelo, Daniel J., Vinod Pullarkat, Miguel Piris‐Villaespesa, et al.. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood. 140(Supplement 1). 1512–1513. 12 indexed citations

Tremblay, Douglas, Lukas Ronner, Nikolai A. Podoltsev, et al.. (2021). Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research. 109. 106629–106629. 2 indexed citations

Maurer, Marcus, Vito Sabato, Katrin Hartmann, et al.. (2020). Results from PIONEER: A randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM). University of Southern Denmark Research Portal (University of Southern Denmark). 1 indexed citations

Akin, Cem, Hanneke Oude Elberink, Jason Gotlib, et al.. (2020). PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy. Journal of Allergy and Clinical Immunology. 145(2). AB336–AB336. 13 indexed citations

Oh, Stephen T., Moshe Talpaz, Aaron T. Gerds, et al.. (2018). Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. Blood. 132(Supplement 1). 4282–4282. 4 indexed citations

Rampal, Raajit K., John Mascarenhas, Heidi Kosiorek, et al.. (2018). Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Advances. 2(24). 3572–3580. 44 indexed citations

Sissolak, Gerhard, et al.. (2015). Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa. Clinical Lymphoma Myeloma & Leukemia. 15(12). 803–810. 3 indexed citations

Stein, Brady L., Stephen T. Oh, Dmitriy Berenzon, et al.. (2015). Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F. Journal of Clinical Oncology. 33(33). 3953–3960. 45 indexed citations

Heaney, Mark, et al.. (2013). Polycythemia vera and essential thrombocythemia. Current Opinion in Hematology. 20(2). 169–175. 9 indexed citations

10.

Mascarenhas, John, Mark Heaney, Vesna Najfeld, et al.. (2012). Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research. 36(12). 1500–1504. 37 indexed citations

11.

Mallikaratchy, Prabodhika, Alessandro Ruggiero, Jeffrey R. Gardner, et al.. (2010). A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Research. 39(6). 2458–2469. 156 indexed citations

12.

Heaney, Mark, Edmond L. Toy, Francis Vekeman, et al.. (2009). Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia. Cancer. 115(20). 4839–4848. 30 indexed citations

13.

Heaney, Mark, Jeffrey R. Gardner, Nicos Karasavvas, et al.. (2008). Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs. Cancer Research. 68(19). 8031–8038. 169 indexed citations

14.

O’Connor, Owen A., Mark Heaney, Lawrence B. Schwartz, et al.. (2005). Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies. Journal of Clinical Oncology. 24(1). 166–173. 345 indexed citations

15.

She, Yuhong, Michael J. Soskis, Christopher P. Borella, et al.. (2004). Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. Journal of Clinical Investigation. 114(8). 1107–1116. 83 indexed citations

16.

Aliff, Timothy, P. Maslak, Joseph G. Jurcic, et al.. (2003). Refractory Aspergillus pneumonia in patients with acute leukemia. Cancer. 97(4). 1025–1032. 172 indexed citations

17.

Golde, David W., et al.. (2002). Cladribine Underdosing in Hairy-cell Leukemia: a Cause for Apparent Response Failure. Leukemia & lymphoma. 43(2). 365–367. 2 indexed citations

18.

Rivas, Coralia I., Juan Carlos Vera, Fernando Delgado‐López, et al.. (1998). Expression of Granulocyte-Macrophage Colony-Stimulating Factor Receptors in Human Prostate Cancer. Blood. 91(3). 1037–1043. 36 indexed citations

19.

Heaney, Mark & David W. Golde. (1998). Soluble receptors in human disease. Journal of Leukocyte Biology. 64(2). 135–146. 149 indexed citations

20.

Vera, Juan Carlos, et al.. (1995). N-Glycosylation of the Human Granulocyte-Macrophage Colony-stimulating Factor Receptor α Subunit Is Essential for Ligand Binding and Signal Transduction. Journal of Biological Chemistry. 270(41). 24580–24584. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact